MetaCap

Jupiter Neurosciences (JUNS) vs PharmaCyte Biotech (PMCB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.

Summary

PharmaCyte Biotech is the larger company by market cap ($4.3 million vs $3.7 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JUNS-2.46%PMCB-2.02%
+0%-1%-3%
Oct 7, 20261 yearOct 8, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JUNS versus PMCB key metrics
MetricJUNSPMCB
Share price$2.77$0.3974
Market cap$3.65M$4.27M
1-day change-2.46%-2.02%
Forward P/E46.17—
EPS (TTM)$-18.94$-2.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$135.75$1.51
52-week low$2.25$0.3339
Distance from 52-week high-97.96%-73.68%
Average volume983.10K205.72K
Shares outstanding1.32M10.74M
Employees52
SectorHealthcareHealthcare
IndustryBiotechnologyBiotechnology

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Jupiter Neurosciences

JUNS stock →

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements.

Healthcare · Biotechnology · 5 employees

About PharmaCyte Biotech

PMCB stock →

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.

Healthcare · Biotechnology · 2 employees

JUNS vs PMCB FAQ

Which is bigger, Jupiter Neurosciences or PharmaCyte Biotech?

PharmaCyte Biotech (PMCB) is larger, with a market capitalization of $4.27M compared with $3.65M for Jupiter Neurosciences (JUNS).

Are Jupiter Neurosciences and PharmaCyte Biotech in the same industry?

Yes. Both are classified in the Biotechnology industry within the Healthcare sector.

More comparisons